Search Results - "Newrzela, S"

Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma by Hartmann, S, Schuhmacher, B, Rausch, T, Fuller, L, Döring, C, Weniger, M, Lollies, A, Weiser, C, Thurner, L, Rengstl, B, Brunnberg, U, Vornanen, M, Pfreundschuh, M, Benes, V, Küppers, R, Newrzela, S, Hansmann, M-L

“…Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)—a subtype of Hodgkin lymphoma (HL)—is characterized by a low content of tumor cells, the lymphocyte…”
Get full text

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL by Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Pützer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ventura Ferreira, M. S., Beier, F., Altmüller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Brümmendorf, T. H., Nürnberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M.-H., Mustjoki, S., Newrzela, S., Frommolt, P., Herling, M.

“…T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in…”
Get full text

Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling by Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H.H., Mayer, P., Kondo Ados, A., Wahnschaffe, L., Braun, T., Müller, T.A., Wagle, P., Bouska, A., Neumann, T., Pützer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Göx, H.J.M., Rappl, G., Altmüller, J., Kotrová, M., Persigehl, T., Hopfinger, G., Hansmann, M.L., Schlößer, H., Stilgenbauer, S., Dürig, J., Mougiakakos, D., von Bergwelt-Baildon, M., Roeder, I., Hartmann, S., Hallek, M., Moriggl, R., Brüggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H., Herling, M.

“…T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are…”
Get full text

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine by Pützer, S., Varghese, L., von Jan, J., Braun, T., Giri, A. K., Mayer, P., Riet, N., Timonen, S., Oberbeck, S., Kuusanmäki, H., Mustjoki, S., Stern, M.-H., Aittokallio, T., Newrzela, S., Schrader, A., Herling, M.

Get full text

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine by Pützer, S., Varghese, L., von Jan, J., Braun, T., Giri, A. K., Mayer, P., Riet, N., Timonen, S., Oberbeck, S., Kuusanmäki, H., Mustjoki, S., Stern, M.-H., Aittokallio, T., Newrzela, S., Schrader, A., Herling, M.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance by Spinner, S, Crispatzu, G, Yi, J-H, Munkhbaatar, E, Mayer, P, Höckendorf, U, Müller, N, Li, Z, Schader, T, Bendz, H, Hartmann, S, Yabal, M, Pechloff, K, Heikenwalder, M, Kelly, G L, Strasser, A, Peschel, C, Hansmann, M-L, Ruland, J, Keller, U, Newrzela, S, Herling, M, Jost, P J

“…T lymphocyte non-Hodgkin's lymphoma (T-NHL) represents an aggressive and largely therapy-resistant subtype of lymphoid malignancies. As deregulated apoptosis…”
Get full text

T-cell receptor diversity prevents T-cell lymphoma development by Newrzela, S, Al-Ghaili, N, Heinrich, T, Petkova, M, Hartmann, S, Rengstl, B, Kumar, A, Jäck, H-M, Gerdes, S, Roeder, I, Hansmann, M-L, von Laer, D

“…Mature T-cell lymphomas (MTCLs) have an extremely poor prognosis and are much less frequent than immature T-cell leukemias. This suggests that malignant…”
Get full text

Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms by Eißmann, M, Melzer, I M, Fernández, S B M, Michel, G, Hrabě de Angelis, M, Hoefler, G, Finkenwirth, P, Jauch, A, Schoell, B, Grez, M, Schmidt, M, Bartholomae, C C, Newrzela, S, Haetscher, N, Rieger, M A, Zachskorn, C, Mittelbronn, M, Zörnig, M

“…AVEN has been identified as an inhibitor of apoptosis, which binds to the adaptor protein, APAF-1, and thereby prevents apoptosome formation and mitochondrial…”
Get full text

88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer by Schmidt, M., Vogler, I., Derhovanessian, E., Omokoko, T., Godehardt, E., Attig, S., Cortini, A., Newrzela, S., Grützner, J., Bolte, S., Langer, D., Eichbaum, M., Lindman, H., Pascolo, S., Schneeweiss, A., Sjöblom, T., Türeci, Ö., Sahin, U.

Get full text

Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling by Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H. H., Mayer, P., Kondo Ados, A., Wahnschaffe, L., Braun, T., Müller, T. A., Wagle, P., Bouska, A., Neumann, T., Pützer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Göx, H. J. M., Rappl, G., Altmüller, J., Kotrová, M., Persigehl, T., Hopfinger, G., Hansmann, M. L., Schlößer, H., Stilgenbauer, S., Dürig, J., Mougiakakos, D., von Bergwelt-Baildon, M., Roeder, I., Hartmann, S., Hallek, M., Moriggl, R., Brüggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H., Herling, M.

“…There is a Blood Commentary on this article in this issue. T-PLL cells resemble activated T-lymphocytes with augmented memory-type effector functions including…”
Get full text

TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy by Preuss, Ellen, Treschow, Alexandra, Newrzela, Sebastian, Brücher, Daniela, Weber, Kristoffer, Felldin, Ulrika, Alici, Evren, Gahrton, Gösta, von Laer, Dorothee, Dilber, M Sirac, Fehse, Boris

“…Conditional elimination of infused gene-modified alloreactive T cells, using suicide gene activation, has been shown to be an efficient strategy to abrogate…”
Get more information

Superior performance of the novel suicide gene TK.007 in adoptive immunotherapy models both in vitro and in vivo by Preuss, E, Treschow, A, Newrzela, S, Brucher, D, Weber, K, Otte, J, Felldin, U, Alici, E, von Laer, D, Dilber, S, Fehse, B

Get full text